Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer

被引：0

作者：

Takahashi, Toshiaki ^{[1
]}

Yamamoto, Nobuyuki ^{[1
]}

Nukiwa, Toshihiro ^{[2
]}

Mori, Kiyoshi ^{[3
]}

Tsuboi, Masahiro ^{[4
]}

Horai, Takeshi ^{[5
]}

Masuda, Noriyuki ^{[6
]}

Eguchi, Kenji ^{[7
]}

Mitsudomi, Tetsuya ^{[8
]}

Yokota, Soichiro ^{[9
]}

Segawa, Yoshihiko ^{[10
]}

Ichinose, Yukito ^{[11
]}

Fukuoka, Masahiro ^{[12
]}

Saijo, Nagahiro ^{[13
]}

机构：

[1] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[2] Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Sendai, Miyagi 980, Japan

[3] Tochigi Canc Ctr, Dept Med Oncol, Div Thorac Oncol, Mibu, Tochigi, Japan

[4] Tokyo Med Univ, Dept Surg, Tokyo, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Thorac Ctr, Tokyo, Japan

[6] Kitasato Univ, Grad Sch Med Sci, Dept Resp Med, Kanagawa, Japan

[7] Tokai Univ, Sch Med, Dept Med Oncol, Kanagawa 2591100, Japan

[8] Aichi Canc Ctr Hosp, Dept Thorac Surg, Aichi, Japan

[9] Toneyama Natl Hosp, Natl Hosp Org, Dept Resp Med, Osaka, Japan

[10] Shikoku Canc Ctr, Natl Hosp Org, Dept Med & Thorac Oncol, Shikoku, Ehime, Japan

[11] Kyushu Natl Canc Ctr, Natl Hosp Org, Dept Thorac Oncol, Fukuoka, Japan

[12] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 589, Japan

[13] Natl Canc Ctr Hosp E, Chiba, Japan

来源：

ANTICANCER RESEARCH | 2010年 / 30卷 / 02期

关键词：

Non-small cell lung cancer; erlotinib; Tarceva; EGFR-TKIs; EGFR mutation; phase II; TYROSINE-KINASE INHIBITOR; SOLID TUMORS; PHARMACOKINETICS; EFFICACY; BENEFIT; GEFITINIB; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC). Patients and Methods: This was a multicentre, open-label phase 11 study of erlotinib (150 mg/day) in patients with stage IIIB or IV NSCLC. The primary endpoint was the objective tumour response rate. Results: Of the 46 patients, 13 were assessed to have a partial response and 9 had stable disease. The median duration of response was 449 days and time to progression vas 75 days. Median overall survival (OS) was 13.5 months and the 1-year survival rate was 56.5%. The most common adverse events were dermal or gastrointestinal, and were mainly grade 2 or less. An exploratory analysis suggested a link between rash severity and OS. Conclusion: Erlotinib has promising antitumour activity and is generally well tolerated in Japanese patients with previously treated NSCLC.

引用

页码：557 / 563

页数：7

共 50 条

[31] Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
Nishio, Makoto
Hida, Toyoaki
Atagi, Shinji
Sakai, Hiroshi
Nakagawa, Kazuhiko
Takahashi, Toshiaki
Nogami, Naoyuki
Saka, Hideo
Takenoyama, Mitsuhiro
Maemondo, Makoto
Ohe, Yuichiro
Nokihara, Hiroshi
Hirashima, Tomonori
Tanaka, Hiroshi
Fujita, Shiro
Takeda, Koji
Goto, Koichi
Satouchi, Miyako
Isobe, Hiroshi
Minato, Koichi
Sumiyoshi, Naoki
Tamura, Tomohide
ESMO OPEN, 2017, 2
[32] Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer
Halmos, Balazs
Pennell, Nathan A.
Fu, Pingfu
Saad, Shumaila
Gadgeel, Shirish
Otterson, Gregory A.
Mekhail, Tarek
Snell, Michael
Kuebler, Philip
Sharma, Neelesh
Dowlati, Afshin
ONCOLOGIST, 2015, 20 (11): : 1298 - 1303
[33] Phase 1b study of capecitabine and erlotinib in advanced non-small cell lung cancer
Lu, S.
Popat, S.
Puglisi, M.
Kaudeer, N.
Gennatas, S.
Hewish, M.
Ayite, B.
Bhosle, J.
O'Brien, M.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S828 - S828
[34] Randomized phase II trial of radiotherapy with or without erlotinib in patients with locally advanced or unresectable non-small cell lung cancer
Martinez, E.
Martinez, M. T.
de la Torre, A.
Valcarcel, F.
Perez, A.
Domine, M.
Amador, M. L.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S510 - S510
[35] Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
Kim, Seung Tae
Uhm, Ji Eun
Lee, Jeeyun
Sun, Jong-mu
Sohn, Insuk
Kim, Seon Woo
Jung, Sin-Ho
Park, Yeon Hee
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
LUNG CANCER, 2012, 75 (01) : 82 - 88
[36] Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
Ahn, J.
Kim, S.
Ahn, M.
Lee, J.
Uhm, J.
Sun, J.
Park, K.
Park, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[37] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)
Lind, Joline S.
Dingemans, Anne-Marie C.
Groen, Harry J.
Smit, Egbert F.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S412 - S413
[38] A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients.
Horn, Leora
Li, Chung-I
Pao, William
Keedy, Vicki Leigh
Johnson, David H.
Carbone, David P.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC)
Lind, J. S.
Dingemans, A. C.
Groen, H. J.
Smit, E. F.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[40] A phase II clinical and PET study of erlotinib and bexarotene for heavily pretreated advanced non-small cell lung cancer (NSCLC)
Dragnev, K. H.
Rigas, J. R.
Seltzer, M.
DiSalvo, W.
Simeone, S.
Johnstone, D.
Nugent, W.
Dmitrovsky, E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →